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We previously cloned Siva-1 by using the cytoplasmic tail of CD27,
a member of the tumor necrosis factor receptor family, as the bait
in the yeast two-hybrid system. The Siva gene is organized into
four exons that code for the predominant full-length Siva-1 tran-
script, whereas its alternate splice form, Siva-2, lacks exon 2 coding
sequence. Various groups have demonstrated a role for Siva-1 in
several apoptotic pathways. Interestingly, the proapoptotic prop-
erties of Siva-1 are lacking in Siva-2. The fact that Siva-1 is partly
localized to mitochondria despite the absence of any mitochondrial
targeting signal, it harbors a 20-aa-long putative amphipathic
helical structure that is absent in Siva-2, and that its expression is
restricted to double-positive (CD3, CD4, CD8) thymocytes like
BCL-XL, prompted us to test for a potential interaction between
Siva-1 and BCL-XL. Here, we show that Siva-1 binds to and inhibits
BCL-XL-mediated protection against UV radiation-induced apopto-
sis. Indeed, the unique amphipathic helical region (SAH) present in
Siva-1 is required for its binding to BCL-XL and sensitizing cells to
UV radiation. Natural complexes of Siva-1BCL-XL are detected in
HUT78 and murine thymocyte, suggesting a potential role for
Siva-1 in regulating T cell homeostasis.
Apoptosis, or programmed cell death, and cell survival areintimately connected, and any shift in the equilibrium
between these two important cell functions can cause disease.
The principal mediators belong to the BCL-2 and tumor necrosis
factor receptor (TNFR) families (1–3). The discovery of BCL-2,
a powerful promoter of cell survival, was soon followed by the
identification of several proteins with structural similarity to
BCL-2. There are four regions of homology termed BH domains;
BCL-2 and BCL-XL have all four domains, whereas BAX and
BAK, the proapoptotic members of the family, lack the BH4
domain. Also included in this family are several potent apoptotic
molecules that have only a minimal BH3 domain (BAD and
BID) (1–3).
BCL-2 and BCL-XL have a conserved transmembrane region
(TM) toward the carboxy terminus that localizes these proteins
to the outer mitochondrial membrane, the outer leaflet of the
nuclear membrane, and the endoplasmic reticulum. The bulk of
the protein projects into the cytoplasm. Although BAX has such
a TM region, in normal cells, it appears to be cytosolic and
localizes to the mitochondria upon induction of apoptosis. The
principal site of action for the BCL-2 family members seems to
be the mitochondria (4–6). The proapoptotic members bind via
their BH3 domain to the cleft formed by the BH1, BH2, and BH3
domains of the antiapoptotic members BCL-2 and BCL-XL (1–3,
7). Interestingly, the BH3 domain is a part of the amphipathic
helix, underscoring the importance of the amphipathic helical
structures in protein–protein interactions.
Various members of the TNFR family regulate cell prolifer-
ation and death by means of their interaction with specific
intracellular signaling molecules that can be divided broadly into
two groups based on the presence of either a death or a
TNFR-associated factor (TRAF) domain (1). By using the
cytoplasmic tail of CD27, a member of the TNFR family, as the
bait in the yeast two-hybrid system, we originally cloned Siva-1
(8, 9), which was subsequently shown to play a role in multiple
apoptotic pathways (10–14). The fact that it has a death TRAF
domain and, in addition, that its cysteine-rich carboxy terminal
region has a zinc finger composed of only cysteines makes Siva-1
unique.
Although Siva-1 lacks any of the known BH domains, we show
that it specifically interacts with BCL-XL through a 20-aa long
amphipathic helix, and that it inhibits BCL-XL-mediated pro-
tection against UV radiation-induced apoptosis.
Materials and Methods
Reagents. The antibodies used in this study are commercially
available [anti-green fluorescent protein (GFP) rabbit antibody,
anti-glutathione S-transferase (GST) mouse monoclonal, anti-
BCL-XL mouse monoclonal, and anti-BCL-2 mouse monoclonal
were obtained from Santa Cruz Biotechnology, the anti-CD3
mouse was from PharMingen]; the rabbit polyclonal anti-
BCL-XL was the kind gift of L. Boise (Univ. of Miami, Miami,
FL). The generation of anti-Siva rabbit antiserum has been
described (9). Mitotracker Green FM and Hoechst 33342 were
obtained from Molecular Probes. The HeLa cells permanently
transfected with pEGFP and pEGFP-BCL-XL plasmids were the
kind gift of W. Marshall (Univ. of Massachusetts, Worcester,
MA), and we generated the MCF7 transfectants expressing GFP
and GFP-BCL-XL.
Molecular Modeling. The secondary structure predictions are
according to Garnier et al. (15) and NNPREDICT program. The
modeling of the SAH was done as a right-handed -helix by using
INSIGHT II, V.98 (Micron Separations) on a Silicon Graphics Iris
workstation.
Various Constructs and Recombinant Proteins. Siva-1 and -2 were
cloned inframe into pMT2 vector in the EcoR1 site downstream
of GST. The Siva1-36–55 and 130–149 deletion mutants were
generated by using the QuickChange mutagenesis kit from
Stratagene and pMT2-GST-Siva-1 as the template. The fidelity
of the constructs was confirmed by sequencing. By using the
pGEX system, the GST and GST-Siva-1 proteins were expressed
in DH5 and purified according to the manufacturer’s protocol
(Amersham Pharmacia); the generation of the BCL-XL frag-
ment (lacking the 20 amino acids from the carboxy terminus) has
been described (16).
Abbreviations: GFP, green fluorescent protein; GST, glutathione S-transferase; WCL,
whole-cell lysate; SAH, Siva-1 amphipathic helical region; DP, double-positive.
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Protein and Immunoprecipitations. To demonstrate direct binding,
varying amounts of recombinant purified BCL-XL protein were
mixed with 25 g of purified GST or GST-Siva-1 protein, and
glutathione Sepharose 4B beads were used to precipitate the
GST protein complexes. The binding between Siva-1 and
BCL-XL in Cos-7 cells using transient transfections was demon-
strated as described (8, 9), except that we also used sodium
deoxycholate (0.1%) in addition to Nonidet P-40 (1% volvol)
both for lysis and for washing the GST protein precipitates. GFP
and the GST proteins were visualized by using anti-GFP rabbit
antiserum (1:1,000) and anti-GST monoclonal antibodies (1:500)
respectively. Whole-cell lysates (WCLs) were monitored for
relative levels of protein expression by immunoblotting. Natural
complexes of Siva-1 and BCL-XL were detected by using anti-
BCL-XL antibody beads and anti-rabbit IgG beads coated with
anti-Siva antibody. In competition experiments, varying concen-
trations of the 20-aa-long synthetic SAH peptide or an equivalent
irrelevant peptide were directly added to the cell lysates followed
by protein precipitation using glutathione Sepharose 4B beads.
Immunofluorescence Staining, Confocal Microscopy, and Flow Cytom-
etry. HeLa and COS-1 cells were transiently transfected with
pSR -Siva-1-HA with or without the pEGFP-BCL-XL plasmid.
After 2 days, the cells were washed and fixed with paraformal-
dehyde and permeabilized with 0.1% Triton X-100. Nonspecific
binding was blocked with goat serum and then treated with
rhodamine-conjugated anti-HA antibody (1:200). To demon-
strate colocalization of Siva-1 to mitochondria, we used HeLa
cells expressing Siva-1-HA protein and mitotracker Green FM.
Distribution of Siva-1 in various types of murine thymocytes
isolated from newborn mice thymuses was determined essen-
tially as described (17). After differentially labeling CD4 and
CD8, the thymocytes were permeabilized (0.1% Nonidet P-40),
blocked with normal goat serum (20% volvol), and then treated
with anti-Siva rabbit antibody followed by anti-rabbit Ig-FITC
(raised in goat). A FACScan cytometer (Becton Dickinson) and
CELLQUEST software were used to analyze and represent data.
Apoptosis Assay. MCF7 permanent transfectants were transiently
transfected with the various plasmids by using Lipofectamine
and a day later were exposed to UV radiation (2 mJcm2 for 1
min). After 5 h, the cells were treated with Hoechst 33342 (1
gml) and incubated at 37°C for 10 min. The cells and their
nuclei were photographed with an inverted UV microscope
(Nikon Diaphot 200) and analyzed by IMAGE-PRO software. The
condensed apoptotic nuclei were physically counted in seven
randomly chosen areas.
Results
The human Siva gene is located on the negative strand of human
chromosome 14(q32–33) (TPA: BK000018). Similar to mouse,
the human gene is organized into four exons coding the full-
length predominant form, Siva-1. Its minor alternate splice form,
Siva-2, lacks the exon 2 coding region (9). Because of the strong
similarity between human and mouse Siva genes, we have
numbered the amino acids in human Siva-1 starting with the
second ATG as the true start codon. Several reasons led us to
investigate the relationship between Siva-1 and BCL-XL. First,
analysis of the region coded by exon 2 in Siva-1 and missing in
Siva-2 revealed a highly conserved 20-aa region (Fig. 1A Top)
that can potentially form an amphipathic helix (SAH; shown as
a pinwheel structure in Fig. 1 A Middle; the space-filling model
of the same is depicted in Fig. 1 A Lower). The region modeled
is slightly larger than a BH3 domain of BID and BAD. However,
there is no homology at the level of primary sequence between
the SAH and BH3 domains. Second, Siva-1 was observed to
localize partly to mitochondria. HA-tagged Siva-1 was tran-
siently expressed in HeLa cells, probed with anti-HA-rhodamine
antibody, and visualized by confocal microscopy. Expression of
Siva-1 was mostly in the cytoplasm (Fig. 1B Upper Right, red), and
the same cell costained with FITC-conjugated-mitochondrial
tracker dye revealed mitochondria as green specks (Upper Left).
Superimposition of the two (Lower Left) demonstrated a signif-
icant portion of Siva-1 localized to mitochondria (yellow). Empty
vector-transfected cells under similar conditions did not reveal
any significant fluorescence (data not shown). The cell boundary
and its nucleus are pictured in the lower right hand corner. Third,
we know that Siva-1 transcripts are highly expressed in human
(8) and mouse thymus (data not shown). Analysis of Siva-1
distribution by flow cytometry in newborn mouse thymocytes
(Fig. 1C), which has mostly double-negative (DN) (CD3,
CD4, CD8) and double-positive (DP) thymocytes (CD3,
CD4, CD8) revealed that almost all of the DP but not the DN
Fig. 1. (A) The sequence in Siva-1 corresponding to the predicted amphi-
pathic helix (Top), its pinwheel representations (Middle), and Connoly space-
filling models (Bottom) are shown. The hydrophobic face of the helix is shown
in the model. The hydrophobic (yellow), the positively charged (red), and the
negatively charged (purple) amino acids are shown. The number of the amino
acid corresponds to the numbering shown in the pinwheel representation,
with one corresponding to 36 and 20 to 55. (B) Intracellular distribution of
expressed Siva-1-HA in HeLa cells was determined by using anti-HA-
rhodamine antibody and Mitotracker Green-FM. Siva-1 is predominantly in
the cytoplasm, (Upper Right, red), the green specks represent mitochondria in
the same cell (Upper Left), and the superimposition of the two suggests
localization of Siva-1 to mitochondria (Lower Left). The morphology of the cell
is shown on the lower right. (C) Siva-1 is expressed mostly in DP murine
thymocytes as evidenced from multicolor flow cytometry (Right). The cells
treated under similar conditions with isotype control or secondary antibodies
failed to label the cells (Left).
6926  www.pnas.orgcgidoi10.1073pnas.102182299 Xue et al.
thymocytes expressed Siva-1, a pattern mirroring BCL-XL ex-
pression (18). Similarly tagged secondary antibodies or normal
serum isotype antibodies failed to label the cells significantly
under comparable conditions. We next investigated the possi-
bility that Siva-1 could interact with BCL-XL.
To demonstrate direct binding between Siva-1 and BCL-XL,
we mixed purified bacterial recombinant GST and GST-Siva-1
proteins with increasing amounts of purified BCL-XL fragment.
GST proteins were precipitated from the mixture by using
glutathione Sepharose beads, subjected to SDSPAGE analysis,
and then immunoblotted with anti-BCL-XL antibody (Fig. 2A).
GST-Siva-1 but not GST alone coprecipitated BCL-XL with
increasing amounts of soluble BCL-XL, demonstrating direct
interaction between Siva-1 and BCL-XL. Also, GST-Siva-1 and
GST-BCL-XL proteins were used to pull down GFP-BCL-XL
and GFP-Siva-1, respectively, from 293T cell lysates (Fig. 2B).
Recombinant GST-BCL-XL precipitated transiently expressed
GFP-Siva-1 but not GFP (Fig. 2B Left), and GST-Siva-1 but not
GST selectively brought down GFP-BCL-XL (Right). WCLs were
assessed for relative levels of GFP-Siva-1 and GFP-BCL-XL
expression; they were comparable (data not shown). Cotrans-
fection of COS-1 cells with GFP-BCL-XL and GST- or GST-
Siva-1- or GST-Siva-2-expressing plasmids, demonstrated the
specific interaction between BCL-XL and Siva-1. Immunoblot-
ting with anti-GFP antibodies revealed that GST-Siva-1 but not
GST-Siva-2 or GST is able to coprecipitate GFP-BCL-XL from
the double transfectants, and GFP is unable to associate with any
of the GST fusion proteins (Fig. 2C; upper left-hand corner,
compare lane 1 with 2 and 3). The same blot was stripped and
probed with anti-GST antibody to demonstrate that the relevant
GST proteins were precipitated from the WCLs (upper right-
hand corner). The relative levels of the expressed proteins in the
WCLs can be seen in the lower panel. Although expression of
GST-Siva-1 is low in comparison to GST-Siva-2 or GST, only
GST-Siva-1 could coprecipitate a significant amount of BCL-XL.
To rule out potential artifacts generated because of cell lysis,
the intracellular colocalization of Siva-1 and BCL-XL was veri-
fied. We transiently coexpressed GFP-BCL-XL and Siva-1-HA
in HeLa cells and detected their localization by using anti-HA-
rhodamine antibodies, which were visualized by confocal mi-
croscopy (Fig. 3A). The pattern of cellular expression of BCL-XL
(green) and Siva-1 (red) shown in (Left) and (Middle), respec-
tively, are very similar. The two patterns are highly superimpos-
able (yellow) with punctate distribution around the nucleus
characteristic of mitochondrial expression, favoring Siva-1
BCL-XL interaction in the cell. By using detergent lysates of
murine thymocytes isolated from newborn mice thymuses, we
immunoprecipitated BCL-XL complexes by using anti-BCL-XL
antibody beads (Fig. 3B). Anti-mouse IgG beads served as a
negative control. Relatively low amounts of Siva-1 were copre-
cipitated with BCL-XL. However, the amount of Siva-1 increased
dramatically after CD3 receptor crosslinking for 30, but after 1
and 2 h, it drastically decreased, accompanied by a shift in its
mobility. In parallel immunoblotting experiments, we verified
that the anti-BCL-XL beads used did precipitate BCL-XL, and
that the protein band seen at about 20 kDa in anti-BCL-XL
immunoprecipitates was similar to the band seen in anti-Siva
immunoprecipitates (data not shown). With untreated HUT78
cells (Fig. 3C), we observed that a significant amount of Siva-1
coprecipitated with BCL-XL but not with BCL-2 or with the
secondary antibody-conjugated beads (Upper). Additionally, we
detected a significant presence of BCL-XL in anti-Siva immu-
noprecipitates but not in other control immunoprecipitations
(Lower). Exposure to UV radiation followed by incubation for 30
min resulted in a slight increase in the amount of the Siva-1
BCL-XL complex (Upper). Although we could detect BCL-XL in
anti-Siva immunoprecipitate at 60 min, we could not detect any
coprecipitated Siva-1 with BCL-XL (compare Upper and Lower).
This anomaly could be because of different affinities and
avidities of the two antibodies used. The fact that the anti-BCL-2
antibody used did precipitate BCL-2 was confirmed in other
experiments (data not shown).
Next, we determined the BCL-XL interacting site in Siva-1.
Data obtained from several deletion and point mutants sug-
gested that the SAH region in Siva-1 could indeed be the
principal mediator of binding to BCL-XL (Fig. 4). To obtain
unambiguous results, we expressed GST-Siva-1SAH and an
equivalent control mutant (Siva-1-130–149) in conjunction
with GFP-BCL-XL in Cos cells (Fig. 4A) and screened for
binding. Protein precipitations revealed significant amounts of
GFP-BCL-XL in the lanes corresponding to either GST-Siva-1 or
GST-Siva-1130–149 but not GST-Siva-1SAH, demonstrating
that the SAH region in Siva-1 is essential for binding to BCL-XL.
Relative levels of GST fusion proteins (Middle) and GFP-
BCL-XL (Lower) in the WCLs were comparable.
The ability of the SAH and an unrelated peptide to displace
GFP-BCL-XL bound to GST-Siva-1 was then determined. Cell
lysates prepared from Cos-1 cells transiently transfected with
GST-Siva-1 and GFP-BCL-XL encoding plasmids were chal-
lenged with varying concentrations of the SAH or a control
Fig. 2. (A) Direct binding between BCL-XL and Siva-1. Recombinant GST-
Siva-1 and GST when mixed with soluble BCL-XL resulted in a dose-dependent
direct interaction between GST-Siva-1 and BCL-XL, despite GST being far in
excess of GST-Siva-1. (B) Recombinant purified GST-Siva-1 and GST-BCL-XL
proteins individually could be used to coprecipitate GFP-BCL-XL and GFP-
Siva-1, respectively, from cell lysates. Cos cells were transiently transfected
with pEGFP-Siva-1 or pEGFP-BCL-XL, lysed, and mixed with equivalent
amounts of either GST-Siva-1 or GST-BCL-XL proteins. The GST protein com-
plexes were precipitated as described in Methods and immunoblotted with
anti-GFP and anti-BCL-XL antibodies. The first lanes (both Left and Right)
represent the relative amounts of the GFP proteins expressed in the WCLs. (C)
GST-Siva-1 but not GST or GST-Siva-2 binds to GFP-BCL-XL. Cos cells were
transiently transfected with GFP-BCL-XL and GST- or GST-Siva-1- or GST-Siva-
2-expressing plasmids. After 48 h, the cells were lysed, and the GST protein
complexes were collected and subjected to SDSPAGE followed by immuno-
blotting with anti-GFP antibody. As shown in the top left hand corner, a
significant amount of GFP-BCL-XL was seen only in the lane corresponding to
GST-Siva-1. GFP itself did not bind to either GST-Siva-1 or GST-Siva-2, as shown
by cotransfection of the empty GFP plasmid with GST-Siva-1 or GST-Siva-2. The
same blot was stripped and probed with ant-GST antibody to demonstrate
that various GST proteins are indeed precipitated (Top Right). The relative
levels of expressed GFP and GST proteins in the WCLs are also shown (Bottom,
Left and Right, respectively).









irrelevant peptide; the GST protein precipitates then were
analyzed for the presence of coprecipitated GFP-BCL-XL. GST-
Siva-1 but not GST coprecipitated a significant amount of
GFP-BCL-XL (Fig. 4B, lane 1) and even at the maximum
concentration of the control peptide tested (200 M), a signif-
icant amount of GFP-BCL-XL coprecipitated with GST-Siva-1
(lane 5). However, by using increasing concentrations of the
SAH peptide, we could compete off the GST-Siva-1-bound
GFP-BCL-XL with complete inhibition of binding at 100 M of
peptide (lane 2). Relative levels of the GFP and GST fusion
proteins in the WCLs were comparable (Fig. 4C).
To analyze the functional significance of the Siva-1–BCL-XL
interaction, we used polyclonal stable MCF7 cells that express
GFP or GFP-BCL-XL. As expected, GFP-BCL-XL transfectants
were highly resistant to UV-induced apoptosis (19), compared
with GFP transfectants (Fig. 5A); only transfection of GST-
Siva-1 but not GST-Siva-2 or GST resulted in abrogation of
BCL-XL-mediated protection (Fig. 5B). Representative pictures
of condensed apoptotic nuclei as evidenced by Hoechst staining
are shown in Fig. 5C. The data obtained by using various deletion
mutants of Siva-1 confirmed our suspicion that the SAH region
in Siva-1 is required for binding to BCL-XL and inhibition of
BCL-XL function (Fig. 5). The deletion of the SAH domain in
Siva-1 resulted in a complete loss of the mutant’s ability to
suppress BCL-XL function, whereas an equivalent deletion
toward the carboxy terminus had no effect (Fig. 5D). Relative
levels of expressed proteins were monitored separately and
found to be comparable (data not shown).
Discussion
Siva-1 is a relatively small proapoptotic molecule we initially
discovered by using the cytoplasmic tail of CD27 (a member of
the TNFR family) as the bait in a yeast two-hybrid system (8).
Unlike Fas and TNFR1, CD27 lacks a death domain in its
relatively short cytoplasmic tail and yet can induce apoptosis.
Several members of the TNFR family that lack a death domain
can also induce apoptosis (20, 21). Siva-1, by interacting with
CD27, probably facilitates cell death by an as-yet-unknown
mechanism. However, several published papers from our group
and others (22–24) and a study using CD27 knockouts (25)
supports a role for CD27 in costimulation. This finding is not
surprising, given the fact that the apoptotic pathways are redun-
Fig. 3. (A) HA-tagged Siva-1 and GFP-BCL-XL were expressed together in HeLa cells and stained with anti-HA-rhodamine antibody. Most of the expressed Siva-1
(red) and BCL-XL (green) colocalize to the same intracellular compartment as seen in the superimposed picture (yellow). (B) The kinetics of natural Siva-1BCL-XL
complexes in murine thymocytes after CD3 crosslinking is shown. Thymocytes obtained from thymuses of newborn mice were cultured on plates coated with
anti-mouse CD3 antibody for the indicated times. Cells (100 106 per sample) were lysed and immunoprecipitated with either anti-rabbit Ig beads (control) or
anti-BCL-XL antibody-linked beads and subjected to immunoblotting with anti-Siva rabbit polyclonal antibody. The amount of coprecipitated Siva-1 increased
by 30 and then decreased, and in the control lane, it did not reveal the presence of significant amount of Siva-1. Immunoblotting with the secondary antibody
alone did not reveal any bands in the corresponding region shown in the figure (data not shown). (C) Hut78 cells were exposed to UV and then incubated for
30 and 60 min, lysed, and subjected to immunoprecipitations. (Upper) Immunoblot probed with anti-Siva antibody. The same blot was stripped and probed with
anti-BCL-XL antibody (Lower). The vertical labels represent various immunoprecipitations. In Hut78 cells not exposed to UV radiation, a significant amount of
Siva-1 was found to be associated with BCL-XL (lane 2, Upper), and the reverse can be seen in the lower panel (lane 1), wherein BCL-XL is coprecipitated with Siva-1
in anti-Siva immunoprecipitates. Secondary antibody-conjugated beads alone or anti-BCL-2 antibody immunoprecipitates did not bring down Siva-1 or BCL-XL.
The amount of Siva-1 in BCL-XL immunoprecipitate increased slightly by 30 min after exposure to UV radiation, and then decreased by 60 min to undetectable
levels (Upper); however, at this time point, BCL-XL could still be found in Siva-1 immunoprecipitate (Lower). The expression of endogenous Siva-1 and BCL-XL
in the WCLs is also shown (last lanes, Upper and Lower).
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dant, and silencing a single gene may not reveal its complete
plethora of actions. For instance, lpr mice (Fas knockouts) suffer
from lymphoproliferative disorders (26), whereas the TNFR1
knockouts do not exhibit any of the disease symptoms (27),
although both are known potent inducers of apoptosis. The
FasTNFR1 double knockouts however develop with a much
more severe form of the disease with an early onset and
significantly higher mortality rates than the single Fas knockout
mice (28). Thus, it is possible that CD27 may be functioning in
vivo with other receptors. The antiapoptotic BCL-2 family
members do inhibit TNFR1-induced apoptosis (19); however,
the physiological relevance of CD27-induced apoptosis and
its connection, if any, to Siva-1 and BCL-XL remains to be
established.
The human Siva gene is located on chromosome 14 (q32–33,
negative strand) and interestingly, this region is targeted for
chromosomal translocation t(14:18)(q32:q21) seen in various
lymphomas (reviewed in ref. 3). The regulation of Siva-1 in these
cancers remains to be determined. BCL-2 prolongs cell survival
and, in cooperation with c-myc, can immortalize pre-B cells (29).
Overexpression of BCL-2 in B cells and T cells increases the
incidence of B cell lymphomas (18) and T cell leukemias (30) and
is further enhanced in transgenic mice that also express myc (31).
Loss of function mutations in BAX have been linked to increased
incidence of cancer (32, 33), thus characterizing BAX as a tumor
suppressor. Siva-1 binds to BCL-XL and abrogates its function,
suggesting a possible tumor-suppressor role. A recent study
demonstrating the down regulation of Siva gene transcription
along with the tumor suppressor p53 and TOSO in colorectal
cancer (34) supports this contention. CC2TIP-30, a Ser-Thr
kinase and known metastasis suppressor, when expressed in
SCLC (small cell lung cancer) cells, resulted in a substantial
increase in the expression of two proapoptotic genes, BAD and
Siva, culminating in cell death (12). These studies suggest a
potential role for Siva in physiological cell death.
The Siva-1 SAH domain is highly conserved, with 75% identity
between human and mouse and 95% identity between mouse
and rat (8–10), and seems to be the principal mediator of binding
to BCL-XL. The results presented here suggest the possibility of
direct binding between Siva-1 and BCL-XL. In experiments
demonstrating the interaction between Siva-1 and BCL-XL, we
used sodium deoxycholate, an ionic detergent, both for cell lysis
and subsequent washes of GST precipitates, suggesting that the
interaction between Siva-1 and BCL-XL is relatively strong. The
SAH region has no homology to other known BH3 domains, and,
therefore, we anticipate its binding region in BCL-XL to be
unique. This is also supported by the fact that deletion of the first
half of the SAH region in Siva-1 results in complete loss of
binding to BCL-XL and inhibition of its function (data not
shown). One of the reasons we chose to investigate Siva-1
association with BCL-XL is that the expression of Siva-1 in
thymocytes is similar to that of BCL-XL (35). In vivo studies have
clearly demonstrated a role for BCL-XL in the survival of DP
thymocytes (35), and the fact that thymocytes harbor natural
complexes of Siva-1BCL-XL suggests a physiological antago-
nistic role for Siva-1 in the survival of DP thymocytes.
CD3 crosslinking and UV radiation induced significant kinetic
changes in the Siva-1BCL-XL complexes, suggesting a role for
other players or posttranslational modifications, as is the case
Fig. 4. (A) Deletion of the SAH region in Siva-1 but not an unrelated
downstream region results in loss of BCL-XL binding. Various plasmids were
coexpressed with pEGFP-BCL-XL in Cos cells and the lysates were subjected to
protein precipitations by using the glutathione beads. -GFP immunoblot
(Top) demonstrates coprecipitation of GFP-BCL-XL with the control deletion
(GST-Siva-1130–149) but not SAH deletion mutant of Siva-1 (GST-Siva-136–
55). Relative levels of GST-fusion proteins in the WCLs (Middle). Expression of
GFP-BCL-XL (Bottom). (B) SAH peptide but not excess of irrelevant peptide
competes off GFP-BCL-XL bound to GST-Siva-1. To the lysates containing
expressed GST-Siva-1 and GFP-BCL-XL, various concentrations of the SAH
peptide or irrelevant peptide (200 M) were added, and the GST-Siva-1
protein complexes were immunoblotted with anti-GFP antibody. The GFP-
BCL-XL bound to GST-Siva-1 (lane 1) was competed off completely at 100 M
SAH peptide (lane 2) but not with irrelevant peptide at 200 M (lane 5). GST
alone did not coprecipitate any GFP-BCL-XL (lane 6). (C) The left-hand panel
represents the relative expression of GFP-BCL-XL; the right-hand panel repre-
sents the relative expression of the GST and GST-Siva-1 proteins in the WCLs
used in the competition experiment shown in B.
Fig. 5. (A) GFP but not GFP-BCL-XL stable MCF7 transfectants are highly
susceptible to UV radiation-induced apoptosis. (B) Transient expression of
GST-Siva-1 but not GST or GST-Siva-2 results in loss of protection against UV
radiation-induced apoptosis in BCL-XL transfectants. (C) Representative pic-
tures of apoptotic nuclei seen in B by staining with Hoechst are shown. (D)
Deletion of the SAH domain in Siva-1 (36–55) but not an irrelevant region
(130–149) results in the complete loss of its ability to suppress BCL-XL
function.









with some of the BCL-2 family members. For instance, conver-
sion of BID to tBID by active caspase 8 makes its BH3 domain
accessible (36, 37). BAD, upon SerThr phosphorylation, is
sequestered by 14–3-3 and inactivated (38, 39). We recently
showed that Siva-1 binds to ARG (abl-related tyrosine kinase)
and is phosphorylated on Y34, rendering cells highly susceptible
to reactive oxygen species-induced apoptosis (11). Therefore, it
is possible that the observed kinetic changes in Siva-1BCL-XL
complexes could be the result of posttranslational modifications.
Although Siva-1 can bind to and inhibit BCL-XL function, the in
vivo functional link between the two remains to be established.
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